BioWorld

Dec. 2, 2009

Protalix: $115M Gaucher's Deal with Pfizer is Just the Beginning

Shares of Protalix BioTherapeutics Inc. dipped 13.7 percent on Tuesday after the biotech unveiled a $115 million profit-sharing deal with Pfizer Inc. for Gaucher's disease drug Uplyso (taliglucerase alfa). (BioWorld Today) Read More

Synagis, Synergy: Trellis Getting $338M In RSV MedImmune Deal

Forma Moving from Platform to Pipeline with $25M Series B

NewCo News: Syntiron Dressing Up Turkey Vaccine; Possible Human Use

Bayer Schering Bites on BiTE Option for Micromet Antibody

Other News To Note

Clinic Roundup

Today's news in brief

BioWorld

BioWorld briefs for Jan 29, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Jan. 28, 2026.

DNA mutations or genetic disorder concept art

Biallelic variants in COX18 identified as cause of Charcot-Marie-Tooth disease

BioWorld Science

Charcot-Marie-Tooth (CMT) disease is a group of clinically and genetically heterogeneous sensorimotor peripheral neuropathies. It is the most frequent inherited...

Brain-derived tau in blood predicts stroke severity and outcome

BioWorld Science

Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...

Centessa’s CNT-9982 shows promise for MDD

BioWorld Science

Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...